RxDoctor Payments DataLook up a doctor →

Raghotham Patlola, MD

Interventional Cardiology · Lafayette, LANPI 1821095860

Payments from drug & device makers

$76,475in general payments, 2019–2025

Across 358 payments — averaging $213.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Catheter Precision, Inc. FKA Ra Medical Systems, Inc.$58K
  • Angiodynamics, Inc.$9K
  • Philips North America LLC$4K
  • Boston Scientific$822
  • Abbott$751
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$547
  • plus $4K from 38 others

What the payments were for

  • Consulting fees$57,37575%
  • Speaking & faculty fees$3,2004%
  • Food & beverage$7,34210%
  • Education$6,9589%
  • Other$1,6002%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$76,475 in reported general payments places this provider in the 75th percentile of 171 interventional cardiology providers in Louisiana.

See all interventional cardiology providers in Louisiana

Medicare billing

Part B allowed, 2024
$172,214
Medicare patients
733
Services billed
2,274

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban338$266,143
EntrestoSacubitril/Valsartan157$138,860
XareltoRivaroxaban153$127,775
JardianceEmpagliflozin14$16,645
Repatha SureclickEvolocumab23$13,852
EdarbyclorAzilsartan Med/Chlorthalidone26$7,820
Ranolazine ErRanolazine42$3,493
Metoprolol Succinate274$3,324
Carvedilol434$2,464
Rosuvastatin Calcium133$2,210
ClopidogrelClopidogrel Bisulfate294$2,053
Atorvastatin Calcium173$1,641
Clonidine13$1,607
Nifedipine ErNifedipine105$1,562
Losartan Potassium146$1,368

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$168$266,143338 claims
NovartisEntresto$413$138,860157 claims
Johnson & JohnsonXarelto$473$127,775153 claims
Boehringer IngelheimJardiance$114$16,64514 claims
Arbor Pharmaceuticals, Inc.Edarbyclor$38$7,82026 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 171 interventional cardiology providers in Louisiana.

Other interventional cardiology in Lafayette

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →